Novel Oral HAE Drug Measures Up to Injectable Options | HappeningNow.news

Health · 7 views

Novel Oral HAE Drug Measures Up to Injectable Options

Source Summary Published 2h 12m ago Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 7 Community interest
Brief read Under 1 min brief 26 words

Summary

(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed.

Read original at MedPage Today

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page